BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lymphocyte
,
Avian flu virus
,
Quercetin
,
rs3825942
,
IGF1
,
calcium channel activity
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cp 55, 940
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for cp 55, 940
Explore Curated Studies Results
Literature
Most Relevant Literature
CP55940-induced vasorelaxation is endothelial-dependent and mediated by the CB1R through NOS, COX an…
Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthoster…
Age-dependent hormesis-like effects of the synthetic cannabinoid CP55940 in C57BL/6 mice.
Age-dependent hormesis-like effects of the synthetic cannabinoid CP55940 in C57BL/6 mice.
Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocan…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids …
Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myelo…
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ